<p>MannKind Corporation（纳斯达克代码：MNKD - 免费报告）- HC Wainwright 的股票分析师在 9 月 2 日（星期二）向客户和投资者发布的研究报告中提高了对 MannKind 2028 财年每股收益的预期。HC Wainwright 的分析师 B. Folkes 现在预计这家生物制药公司将在该年度发布每股收益 0.38 美元，高于之前预测的 0.37 美元。HC Wainwright 对该股票给予 “买入” 评级，目标价为 11.00 美元。市场普遍预计 MannKind 当前全年的每股收益为 0.10 美元。HC Wainwright 还对 MannKind 2029 财年的每股收益预期为 0.65 美元。</p>
<p>其他一些股票分析师最近也发布了关于 MNKD 的报告。富国银行将 MannKind 的目标价从 9.00 美元上调至 10.00 美元，并在周三的报告中给予该股票 “超配” 评级。加拿大皇家银行在 8 月 26 日（星期二）的报告中将 MannKind 的目标价从 7.00 美元上调至 8.00 美元，并给予该公司 “跑赢大盘” 评级。最后，华尔街 Zen 在 8 月 2 日（星期六）的报告中将 MannKind 的评级从 “买入” 下调至 “持有”。两位研究分析师对该股票给予 “强烈买入” 评级，五位分析师给予该公司股票 “买入” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “买入”，平均目标价为 10.00 美元。</p>
<p><strong>查看我们最新的 MNKD 股票报告</strong></p>
<h2>MannKind 股价下跌 4.0%</h2>
<p>MNKD 的股票在周四以 5.51 美元开盘。MannKind 的 1 年最低价为 3.38 美元，1 年最高价为 7.63 美元。该股票的市值为 16.9 亿美元，市盈率为 50.10，贝塔值为 1.02。该股票的 50 日移动平均价格为 3.93 美元，200 日移动平均价格为 4.44 美元。</p>
<p>MannKind（纳斯达克代码：MNKD - 获取免费报告）最近在 8 月 6 日（星期三）发布了其财报。这家生物制药公司报告本季度每股收益为 0.05 美元，超出分析师一致预期的 0.04 美元，超出幅度为 0.01 美元。MannKind 的股本回报率为-32.60%，净利润率为 10.87%。该公司本季度的收入为 7653 万美元，而分析师预期为 7782 万美元。去年同期，该公司每股收益为 0.05 美元。与去年同期相比，该公司的收入增长了 5.7%。</p>
<h2>MannKind 的内部买卖</h2>
<p>在其他消息中，董事 Steven B. Binder 在 7 月 16 日（星期三）出售了 75367 股 MannKind 股票。该股票以平均价格 3.94 美元出售，总交易额为 296,945.98 美元。交易后，该董事在公司持有 830,508 股，价值 3,272,201.52 美元。此次交易使其持股减少了 8.32%。该交易已在向 SEC 提交的文件中披露，文件可在此链接查看。公司内部人士持有 3.00% 的股票。</p>
<h2>机构投资者对 MannKind 的看法</h2>
<p>一些对冲基金和其他机构投资者最近也买卖了 MNKD 的股票。Dimensional Fund Advisors LP 在第四季度将其在 MannKind 的持仓增加了 40.7%。Dimensional Fund Advisors LP 现在持有 2958219 股该生物制药公司的股票，价值 19022000 美元，此前在上个季度又购买了 855261 股。汇丰控股在第四季度将其在 MannKind 的持仓增加了 49.7%。汇丰控股现在持有 31327 股该生物制药公司的股票，价值 203000 美元，此前在上个季度又购买了 10407 股。Price T Rowe Associates Inc. MD 在第四季度将其在 MannKind 的持仓增加了 12.0%。Price T Rowe Associates Inc. MD 现在持有 175009 股该生物制药公司的股票，价值 1126000 美元，此前在上个季度又购买了 18806 股。北方信托公司在第四季度将其在 MannKind 的持仓增加了 8.1%。北方信托公司现在持有 2777784 股该生物制药公司的股票，价值 17861000 美元，此前在上个季度又购买了 207792 股。最后，Ameriprise Financial Inc.在第四季度将其在 MannKind 的持仓增加了 145.4%。Ameriprise Financial Inc.现在持有 43685 股该生物制药公司的股票，价值 281000 美元，此前在上个季度又购买了 25880 股。机构投资者和对冲基金持有该公司 49.55% 的股票。</p>
<h2>MannKind 公司简介</h2>
<p>（获取免费报告）</p>
<p>MannKind Corporation 是一家生物制药公司，专注于在美国开发和商业化用于内分泌和孤儿肺病的吸入治疗产品。它提供 Afrezza，一种用于改善糖尿病成人血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送设备，提供成人的持续皮下胰岛素输注。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 MannKind</li>
<li>CD 计算器：定期存款计算器</li>
<li>ETF 的回报：3 个可能持续超越的名字</li>
<li>投资于高市盈率成长股</li>
<li>开学购物达到 400 亿美元：3 只值得关注的零售股票</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>字母表股票在躲避严厉的反垄断措施后大幅上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 MannKind 吗？</h2>
<p>在你考虑 MannKind 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 MannKind 并不在名单上。</p>
<p>虽然 MannKind 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

曼恩凯德生物医疗

<p>HC Wainwright 将 MannKind Corporation (NASDAQ:MNKD) 的 2028 财年每股收益预期从 0.37 美元上调至 0.38 美元，维持 “买入” 评级，目标价为 11.00 美元。其他分析师也提高了他们的目标价，富国银行将其上调至 10.00 美元，加拿大皇家银行则上调至 8.00 美元。MannKind 当前的收益共识为每股 0.10 美元。该股票开盘价为 5.51 美元，市值为 16.9 亿美元，市盈率为 50.10。还注意到内部交易活动和机构投资</p>

<p>MannKind Corporation (NASDAQ:MNKD - Free Report) - Stock analysts at HC Wainwright increased their FY2028 earnings per share estimates for MannKind in a research report issued to clients and investors on Tuesday, September 2nd. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of $0.38 for the year, up from their prior forecast of $0.37. HC Wainwright has a &#34;Buy&#34; rating and a $11.00 price target on the stock. The consensus estimate for MannKind's current full-year earnings is $0.10 per share. HC Wainwright also issued estimates for MannKind's FY2029 earnings at $0.65 EPS.</p>
<div class="lb-trans"><p>MannKind Corporation（纳斯达克代码：MNKD - 免费报告）- HC Wainwright 的股票分析师在 9 月 2 日（星期二）向客户和投资者发布的研究报告中提高了对 MannKind 2028 财年每股收益的预期。HC Wainwright 的分析师 B. Folkes 现在预计这家生物制药公司将在该年度发布每股收益 0.38 美元，高于之前预测的 0.37 美元。HC Wainwright 对该股票给予 “买入” 评级，目标价为 11.00 美元。市场普遍预计 MannKind 当前全年的每股收益为 0.10 美元。HC Wainwright 还对 MannKind 2029 财年的每股收益预期为 0.65 美元。</p>
</div><p>A number of other equities analysts have also recently issued reports on MNKD. Wells Fargo &amp; Company raised their target price on MannKind from $9.00 to $10.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday. Royal Bank Of Canada lifted their price objective on MannKind from $7.00 to $8.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, August 26th. Finally, Wall Street Zen cut MannKind from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Buy&#34; and an average target price of $10.00.</p>
<div class="lb-trans"><p>其他一些股票分析师最近也发布了关于 MNKD 的报告。富国银行将 MannKind 的目标价从 9.00 美元上调至 10.00 美元，并在周三的报告中给予该股票 “超配” 评级。加拿大皇家银行在 8 月 26 日（星期二）的报告中将 MannKind 的目标价从 7.00 美元上调至 8.00 美元，并给予该公司 “跑赢大盘” 评级。最后，华尔街 Zen 在 8 月 2 日（星期六）的报告中将 MannKind 的评级从 “买入” 下调至 “持有”。两位研究分析师对该股票给予 “强烈买入” 评级，五位分析师给予该公司股票 “买入” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “买入”，平均目标价为 10.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on MNKD</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MNKD 股票报告</strong></p>
</div><h2>MannKind Trading Down 4.0%</h2>
<div class="lb-trans"><h2>MannKind 股价下跌 4.0%</h2>
</div><p>Shares of MNKD opened at $5.51 on Thursday. MannKind has a 1 year low of $3.38 and a 1 year high of $7.63. The stock has a market cap of $1.69 billion, a P/E ratio of 50.10 and a beta of 1.02. The stock's 50-day moving average price is $3.93 and its two-hundred day moving average price is $4.44.</p>
<div class="lb-trans"><p>MNKD 的股票在周四以 5.51 美元开盘。MannKind 的 1 年最低价为 3.38 美元，1 年最高价为 7.63 美元。该股票的市值为 16.9 亿美元，市盈率为 50.10，贝塔值为 1.02。该股票的 50 日移动平均价格为 3.93 美元，200 日移动平均价格为 4.44 美元。</p>
</div><p>MannKind (NASDAQ:MNKD - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. MannKind had a negative return on equity of 32.60% and a net margin of 10.87%.The firm had revenue of $76.53 million for the quarter, compared to analysts' expectations of $77.82 million. During the same quarter last year, the business earned $0.05 earnings per share. The company's revenue was up 5.7% compared to the same quarter last year.</p>
<div class="lb-trans"><p>MannKind（纳斯达克代码：MNKD - 获取免费报告）最近在 8 月 6 日（星期三）发布了其财报。这家生物制药公司报告本季度每股收益为 0.05 美元，超出分析师一致预期的 0.04 美元，超出幅度为 0.01 美元。MannKind 的股本回报率为-32.60%，净利润率为 10.87%。该公司本季度的收入为 7653 万美元，而分析师预期为 7782 万美元。去年同期，该公司每股收益为 0.05 美元。与去年同期相比，该公司的收入增长了 5.7%。</p>
</div><h2>Insider Buying and Selling at MannKind</h2>
<div class="lb-trans"><h2>MannKind 的内部买卖</h2>
</div><p>In other news, Director Steven B. Binder sold 75,367 shares of MannKind stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $3.94, for a total transaction of $296,945.98. Following the transaction, the director owned 830,508 shares in the company, valued at $3,272,201.52. The trade was a 8.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.00% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Steven B. Binder 在 7 月 16 日（星期三）出售了 75367 股 MannKind 股票。该股票以平均价格 3.94 美元出售，总交易额为 296,945.98 美元。交易后，该董事在公司持有 830,508 股，价值 3,272,201.52 美元。此次交易使其持股减少了 8.32%。该交易已在向 SEC 提交的文件中披露，文件可在此链接查看。公司内部人士持有 3.00% 的股票。</p>
</div><h2>Institutional Investors Weigh In On MannKind</h2>
<div class="lb-trans"><h2>机构投资者对 MannKind 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of MNKD. Dimensional Fund Advisors LP raised its position in MannKind by 40.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,958,219 shares of the biopharmaceutical company's stock valued at $19,022,000 after buying an additional 855,261 shares during the last quarter. Hsbc Holdings PLC raised its position in MannKind by 49.7% in the 4th quarter. Hsbc Holdings PLC now owns 31,327 shares of the biopharmaceutical company's stock valued at $203,000 after buying an additional 10,407 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in MannKind by 12.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 175,009 shares of the biopharmaceutical company's stock valued at $1,126,000 after buying an additional 18,806 shares during the last quarter. Northern Trust Corp raised its position in MannKind by 8.1% in the 4th quarter. Northern Trust Corp now owns 2,777,784 shares of the biopharmaceutical company's stock valued at $17,861,000 after buying an additional 207,792 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in MannKind by 145.4% in the 4th quarter. Ameriprise Financial Inc. now owns 43,685 shares of the biopharmaceutical company's stock valued at $281,000 after buying an additional 25,880 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近也买卖了 MNKD 的股票。Dimensional Fund Advisors LP 在第四季度将其在 MannKind 的持仓增加了 40.7%。Dimensional Fund Advisors LP 现在持有 2958219 股该生物制药公司的股票，价值 19022000 美元，此前在上个季度又购买了 855261 股。汇丰控股在第四季度将其在 MannKind 的持仓增加了 49.7%。汇丰控股现在持有 31327 股该生物制药公司的股票，价值 203000 美元，此前在上个季度又购买了 10407 股。Price T Rowe Associates Inc. MD 在第四季度将其在 MannKind 的持仓增加了 12.0%。Price T Rowe Associates Inc. MD 现在持有 175009 股该生物制药公司的股票，价值 1126000 美元，此前在上个季度又购买了 18806 股。北方信托公司在第四季度将其在 MannKind 的持仓增加了 8.1%。北方信托公司现在持有 2777784 股该生物制药公司的股票，价值 17861000 美元，此前在上个季度又购买了 207792 股。最后，Ameriprise Financial Inc.在第四季度将其在 MannKind 的持仓增加了 145.4%。Ameriprise Financial Inc.现在持有 43685 股该生物制药公司的股票，价值 281000 美元，此前在上个季度又购买了 25880 股。机构投资者和对冲基金持有该公司 49.55% 的股票。</p>
</div><h2>MannKind Company Profile</h2>
<div class="lb-trans"><h2>MannKind 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物制药公司，专注于在美国开发和商业化用于内分泌和孤儿肺病的吸入治疗产品。它提供 Afrezza，一种用于改善糖尿病成人血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送设备，提供成人的持续皮下胰岛素输注。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than MannKind</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Return of the ETFs: 3 Names That Could Keep Outperforming</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MannKind</li>
<li>CD 计算器：定期存款计算器</li>
<li>ETF 的回报：3 个可能持续超越的名字</li>
<li>投资于高市盈率成长股</li>
<li>开学购物达到 400 亿美元：3 只值得关注的零售股票</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>字母表股票在躲避严厉的反垄断措施后大幅上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=MNKD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MannKind Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 MannKind 吗？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MannKind 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 MannKind 并不在名单上。</p>
</div><p>While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MannKind 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 上调了曼恩凯德生物医疗 2028 财年的每股收益预期